Silibinin, a prominent constituent of silymarin, could mitigate motor impairment, neuronal degeneration, and astrocyte activation in a mouse model of PD induced by MPTP through inhibiting extracellular signal-regulated kinase (ERK) and Jun N-terminal kinase (JNK) signaling pathways and COX expression [190]. The gene discussed is MAPK8; the disease is Parkinson disease.